Baxter International Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $815M TTM FCF base; 8% FCF growth years 1-5 (margin recovery from the Kidney Care/Vantive divestiture and cost restructuring, layered on top of ~4% analyst-forecast underlying revenue growth); 4% years 6-10; 8.5% discount rate; 2.5% terminal growth; $7.52B net debt; 517.00M shares outstanding.

Reasoning: Baxter's near-term FCF growth is expected to outpace revenue growth as recent divestitures and restructuring lift margins; a multi-stage DCF captures this margin-driven cash-flow inflection better than a flat-growth model, while reverting to steady healthcare-sector growth in the terminal phase.